Clinical trial of a new chromone compound for systemic treatment of atopic dermatitis.

In a double-blind group comparative study, 14 adults with atopic dermatitis were treated systemically for 6 weeks with a new anti-allergic chromone compound (FPL 57787) 6 mg four times a day. A similar group of 13 adults was given placebo. Both groups improved during the trial in all the clinical assessments without significant differences, but there was a tendency to a decreased use of local treatment (hydrocortisone butyrate) in the active group during the trial. There were no drug-related complaints, but one patient in the active group had transiently elevated liver enzyme levels. Further investigations are warranted.